#ICYMI clinical trials began yesterday for the #COVID19 #vaccine we’re co-developing with @Sanofi. We recently reached agreements with the United States Government and @GOVUK to supply up to 160m doses. Learn more: https://t.co/ONieV6MPPs #coronavirus pic.twitter.com/hCtOJDk6qg
— GSK (@GSK) September 4, 2020
We've announced our new #AI hub in London which will help us reimagine how new medicines are discovered for cancer and other serious diseases. Read more in @standardnews @ArmitageJim https://t.co/WyysxrZZty pic.twitter.com/rylXkh54Ky
— GSK (@GSK) September 3, 2020
By harnessing the power of the immune system and working with our partner @Vir_Biotech we’re accelerating potential antibody therapies to fight #COVID19. Watch this video to learn more: pic.twitter.com/WGVKLELooB
— GSK (@GSK) September 1, 2020
We recently announced a collaboration with Canadian Biopharma @medicagoinc to develop a #COVID19 candidate vaccine combining innovative plant-based and adjuvant technologies. Learn more: https://t.co/qHwbkOtYYV pic.twitter.com/gvp63cmEKf
— GSK (@GSK) August 6, 2020
We’re excited to enter into a strategic collaboration with @CureVacAG to advance mRNA vaccines and monoclonal antibodies targeting infectious diseases. https://t.co/SEcEvCRkfB
— GSK (@GSK) July 20, 2020
We are committed to helping patients with unmet needs. Go #BehindTheScience of how our bodies adapt to low levels of #oxygen and read more about how we are meeting the needs of patients with #anaemia due to chronic kidney disease.
— GSK (@GSK) July 15, 2020
We’re excited to announce that a Phase 1 clinical trial has begun for our #COVID19 vaccine development collaboration with Canadian Biopharma @medicagoinc which combines innovative plant-based and adjuvant technologies. https://t.co/jpe27Ph7yI pic.twitter.com/4yJNvlL9Kl
— GSK (@GSK) July 14, 2020
We’re excited to start a Phase I study to investigate a candidate vaccine against Staphylococcus aureus infections. Interested to know more about how vaccine science helps fight antimicrobial resistance? Watch the #BehindTheScience video to find out#StopSuperbugs #EndAMR pic.twitter.com/7GVfCgSl8W
— GSK (@GSK) July 1, 2020
It’s Blood Cancer Awareness Month #BCAM, and we are proud to support the blood cancer community and reaffirm our commitment to #fightbloodcancers through advancing clinical research and improving patient care. pic.twitter.com/3yq4ph4eZO
— GSK (@GSK) September 11, 2020
The #ERSCongress may have come to a close, but patients continue to be affected by respiratory conditions. Whilst patients are struggling with #asthma or #COPD we will continue to use our decades of experience and expertise to provide solutions. https://t.co/AwNvmdWTGu pic.twitter.com/TdgZJbJg6a
— GSK (@GSK) September 10, 2020
Our head of #AI, Kim Branson, shares more on how #Tech can be a game changer for medicine. #LondonTechWeek #LTW https://t.co/a0vpGDFgQh pic.twitter.com/oCKJ0nlTxA
— GSK (@GSK) September 10, 2020
Yesterday, in a unique pledge, GSK, @pfizer, @AstraZeneca, @sanofi, @moderna_tx, @BioNTech_Group, @JNJNews, @Merck & @Novavax outlined a united commitment to upholding the integrity of the scientific process as we develop a #COVID19 vaccine. Learn more: https://t.co/wJOIvNFVMb pic.twitter.com/zRYOPWjiuL
— GSK (@GSK) September 9, 2020
The current population of 617 million adults aged >65 years will grow to 1,566 million by 2050. At #ERSCongress we’re talking vaccine-preventable diseases in older people living with respiratory disease. pic.twitter.com/dTrexD5XeG
— GSK (@GSK) September 9, 2020
New data on vaccine-preventable diseases in adults with respiratory conditions discussed during #ERSCongress. What is the scientific value of adult vaccination? pic.twitter.com/YJslhv1x84
— GSK (@GSK) September 8, 2020
For some patients with #COPD, the priority is to manage their symptoms, for others the priority is to reduce the risk of exacerbation. Dr Alice Turner explains why managing the risk of exacerbations is an important target. #ERSCongress pic.twitter.com/A06vuFkdOc
— GSK (@GSK) September 8, 2020
Do you know why a COPD exacerbation should not be ignored and appropriate action should be taken to prevent them?
This is why we continue to use our decades of experience and expertise to advance the management of #COPD. #ERSCongress pic.twitter.com/LcNqBThABa— GSK (@GSK) September 8, 2020
Our Chief Medical Officer, GSK Vaccines, Thomas Breuer explains why we’ve joined other biopharm companies in pledging to uphold the integrity of the scientific process in the research and development of a #COVID19 vaccine. https://t.co/7Y0jDQ1Qac #WeStandWithScience pic.twitter.com/bcqnfuF3QJ
— GSK (@GSK) September 8, 2020
We pledge to continue our longstanding commitment to uphold high ethical standards and sound scientific principles in the research and development of a #COVID19 vaccine. #WeStandWithScience, @JNJNews, we encourage you to stand with us. https://t.co/lMRW85iSSV pic.twitter.com/19J9bwaYm1
— GSK (@GSK) September 8, 2020
Listen to Prof David Halpin talk about how real-world studies help to provide information on a wider population of patients. Go #behindthescience to learn more: https://t.co/syyTi3HAR2#ERSCongress #COPD pic.twitter.com/Tcrc4bBJFL
— GSK (@GSK) September 8, 2020
In around half of people with severe asthma, a raised blood level of eosinophils (a type of white blood cell) causes inflammation in the airways, making it difficult to breathe and increasing the risk of an #asthma attack. #ERSCongress pic.twitter.com/sjHC8ul4N4
— GSK (@GSK) September 7, 2020
Over 300 million people globally have #asthma, each affected by their disease in a different way. Could ‘treatable traits’ help guide a more individualised approach to patient care? Go #behindthescience https://t.co/mOL18peUPs
— GSK (@GSK) September 7, 2020
We believe a personalised approach is key to helping people with #asthma.
We continue to use our decades of experience and expertise to find possible treatment solutions for those who still suffer from their symptoms. #ERSCongress pic.twitter.com/kGD0AM95bj— GSK (@GSK) September 7, 2020
358 million people globally have #asthma; how can they all be the same? How do you make treatment decisions based on how asthma affects the individual?
We believe a personalised approach is key to helping people with #asthma. #ERSCongress pic.twitter.com/Hg22CTRSRf— GSK (@GSK) September 7, 2020
The scientific debates we’re having at #ERS2020 could improve respiratory disease management, helping patients keep active, feeling well and out of hospital. #COPD #asthma https://t.co/NtzA86CrQV pic.twitter.com/ZgdhX8Ehxh
— GSK (@GSK) September 6, 2020
We may not be meeting face to face for the #ERS2020, but sharing new data and driving discussion on how we can improve the lives of people with #COPD and #asthma remains as important as ever. https://t.co/SsiLp3ICpn pic.twitter.com/nDDo6wOuDk
— GSK (@GSK) September 4, 2020
As #LondonTechWeek continues, hear from Sir John Bell on how #London has emerged to be the perfect place to house the latest scientific evolution with #medicine and #technology. pic.twitter.com/Yqd5GBN7Ar
— GSK (@GSK) September 4, 2020
#ICYMI: In the last two years we have built a stronger pipeline with a clear focus on immunology. pic.twitter.com/sYsFqyCnhc
— GSK (@GSK) August 11, 2020
Kimberly Smith, Head of R&D at @ViiVHC, our specialist HIV company, reinforces ViiV’s commitment to include more women in HIV research. https://t.co/huix2a2RAT
— GSK (@GSK) August 6, 2020
We’re delighted to have been recognised in the #TimesTop50 employer for women in the UK by @BITC for our commitment to workplace gender equality and creating an environment where women can progress. Learn more: https://t.co/wv0NV7EFqc pic.twitter.com/Zv29O74AOs
— GSK (@GSK) July 30, 2020
Today we announced our Q2 2020 results. Find out more about our performance in the quarter with our CEO, Emma. https://t.co/XfQNCI4JYs pic.twitter.com/p5SOqAXtpn
— GSK (@GSK) July 29, 2020
Please read this cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures for our Q2 2020 results. CER% represents constant exchange rates. £% or AER% represents actual exchange rates. $GSK https://t.co/SPl3khzil1
— GSK (@GSK) July 29, 2020
Great news that the @GOVUK has agreed, subject to final contract, to purchase 60m doses of the #COVID19 vaccine candidate we’re co-developing with Sanofi combining our pandemic adjuvant system with @Sanofi’s recombinant protein technology. https://t.co/ppganW4Ymm
— GSK (@GSK) July 29, 2020
“I am seeing unprecedented levels of collaboration as companies come together to share ideas”. Phil Thomson, our President of Global Affairs, speaking on building future health resilience at the recent UN Global Compact Leaders Summit. https://t.co/p4SmKVcy6O
— GSK (@GSK) July 28, 2020
We’ve launched our NEW free and fun #STEMatHome experiments for young people whilst learning from home. Discover these and more #STEM resources at https://t.co/UdfdJfO8Kp pic.twitter.com/mJUaHXLvYN
— GSK (@GSK) July 28, 2020
Hepatitis is the second largest infectious killer worldwide. It’s estimated nearly 290 million people are living undiagnosed with viral hepatitis worldwide. Visit the WHA website to learn more: https://t.co/xHuB8qyAta Help #Findthemissingmillions on #WorldHepatitisDay pic.twitter.com/o3ElCYsBHv
— GSK (@GSK) July 28, 2020
To mark #InternationalSelfCareDay, we’ve highlighted some of our research on the impact that #COVID19 has had on attitudes towards self-care 👇 #SelfCareForAll https://t.co/mvnjLfvnS9 pic.twitter.com/X5wyLmavrW
— GSK (@GSK) July 24, 2020
Our HIV specialist company @ViivHC has today announced the projects which will be supported by its Global #HIV and #COVID19 Emergency Response Fund. https://t.co/54RqoA2ghA
— GSK (@GSK) July 10, 2020
We’re coming together with other leading biopharmaceutical companies to invest in a $1 billion @AMRActionFund aiming to bring 2-4 new #antibiotics to patients by 2030. Go #BehindTheScience to learn about our antibacterial research. https://t.co/c45wo7Cdf0 #antimicrobialresistance
— GSK (@GSK) July 10, 2020
#COVID19 has taught us that the world needs to be better prepared for global health crises. We’re proud to back the @AMRActionFund alongside @IFPMA and others in the #pharma industry. https://t.co/PAh6ek9KfT
— GSK (@GSK) July 10, 2020
We’ve come together with industry to invest in the new @AMRActionFund, a ground-breaking partnership that aims to bring 2-4 new #antibiotics to patients by 2030. Learn more: https://t.co/7bB39vdgyy #AMR https://t.co/W7FFRdm5ds
— GSK (@GSK) July 9, 2020
We need a sustainable pipeline of new #antibiotics to fight #superbugs. On July 9th, we're joining @IFPMA and more than 20 others in #pharma to make a major #AMR announcement – watch this space! https://t.co/FfMTbilOLK
— GSK (@GSK) July 9, 2020
Phil Thomson, our President, Global Affairs, shares his thoughts on how purpose can guide business in building back better through and beyond #COVID19 at the @BITC digital roundtable. https://t.co/SVFvCxjBLK
— GSK (@GSK) July 8, 2020
Our team at GSK Worthing have donated hand sanitiser to protect those at the forefront of the fight against #COVID19 in Sussex, England. Over 300kg of food and toilet rolls were also supplied to the Brighton foodbank to help the community. https://t.co/MoWUFRFhKf pic.twitter.com/9QyjLpN1vI
— GSK (@GSK) July 8, 2020
Finding a cure for HIV may be a challenge, but our specialist company @ViivHC is committed to leave no person living with HIV behind #AIDS2020 #AIDS2020Virtual https://t.co/eW8bqO7veN
— GSK (@GSK) July 7, 2020
We’re proud to be part of the working group to highlight the need for consistent terminology in precision medicine testing to better serve the needs of #cancer patients. https://t.co/vcyikYzcVW
— GSK (@GSK) July 7, 2020
#BreakingNews for #investors and #media: @US_FDA has approved Rukobia in the US. Visit https://t.co/WmsyOlvJtj to find out more.
— GSK (@GSK) July 2, 2020
GSK welcomes this new R&D roadmap from the Government and fully supports the goal of attracting the best scientists from around the world to work in the UK so it continues to be at the forefront of science globally, especially lifesciences. https://t.co/CcFvONvmBu
— GSK (@GSK) July 1, 2020
Our GSK Italy colleagues honored pharmacists with this #ThankYouPharmacists TV and digital commercial, recognising pharmacists across Italy as everyday heroes working hard daily to fight #COVID19. Thank you, GSK Consumer Healthcare Italy! 👏 🇮🇹 pic.twitter.com/yfYaM17w4L
— GSK (@GSK) July 1, 2020
Prof James Chalmers from @dundeeuni explains how exciting research into the lung microbiome is informing the future management of #respiratory disease and could help us to find new treatments. #COPD #asthma pic.twitter.com/NZvsVsfCMI
— GSK (@GSK) June 24, 2020
Delighted to see Prof James Chalmers presenting research @atscommunity virtual clinical trials session. We're proud of our collaboration with @dundeeuni. Discover how the lung microbiome is informing the future management of #respiratory disease: https://t.co/6lINUs9cnT
— GSK (@GSK) June 24, 2020
Our Japan Sales team has donated hand-made masks to a local Ronald McDonald House, a charity which provides a place to stay for families who want to be close to a hospitalised child. Thanks to our employees in Japan for all that you’re doing to fight #COVID19. 👏 🇯🇵 pic.twitter.com/eg0GSWJWUz
— GSK (@GSK) June 24, 2020
GSK and Sanofi to start human trials on Covid-19 vaccine https://t.co/4BAzHhXBEm
— The Guardian (@guardian) September 3, 2020
A massive ‘high-five’ to @GlobalFund for its #COVID19 response efforts to protect and accelerate the hard-won gains made to end the AIDS epidemic and other infectious diseases. No economy is safe until everyone is protected https://t.co/FUQ02NNiU0
— ViiV Healthcare (@ViiVHC) August 12, 2020
Read an article by Phil Thomson, our President, Global Affairs and Jane Nelson from the @Kennedy_School on how innovation, collaboration and purpose can help strengthen health systems and build future health resilience. https://t.co/w3lDbhNwvT
— GSK (@GSK) July 16, 2020
GlaxoSmithKline and Vir Biotechnology are starting a phase 2/3 study of their coronavirus antibody drug. @MegTirrell reports. https://t.co/ZGDN1lC2FI pic.twitter.com/bmH1YCsZCi
— CNBC (@CNBC) August 31, 2020
A coronavirus vaccine being developed in partnership with a British drug company has begun human trials and up to one billion doses are being made for next year https://t.co/f7SJi9txE1
— The Times (@thetimes) September 3, 2020
NEWS: Britain has now secured an extra 60 million doses of a potential #coronavirus vaccine from GSK & Sanofi Pasteur.
This is a great step in our fight against this unprecedented #coronavirus.https://t.co/kiWKFvNneP
— Matt Hancock (@MattHancock) July 29, 2020
Opinion: We risk returning to a time when a simple cut could have lethal consequences and common surgical procedures might be too risky to perform, writes GlaxoSmithKline chief executive Emma Walmsley https://t.co/ycz0L29BFG
— Financial Times (@FinancialTimes) July 14, 2020
Today in the UK there is still stigma and misunderstanding around HIV.@gareththomas14 has decided to #TackleHIV with @ViiVHC and @THTorguk for everyone living with the virus.
You can play your part and help us end stigma around HIV now ➡️ https://t.co/48ofJ6bZME pic.twitter.com/NYrx5e4qEQ
— Tackle HIV (@TackleHIV) June 24, 2020
.@BARDA, @JPEOCBRND, @Sanofi and @GSK are working together at #WarpSpeed to develop & demonstrate large-scale manufacturing of an investigational adjuvanted #COVID19 vaccine. Adjuvant enhances vaccine effectiveness. https://t.co/hPvvndfA59 pic.twitter.com/3RdOJ6q8Jp
— ASPR (@PHEgov) July 31, 2020
We’re partnering w/ @JPEOCBRND, @Sanofi, & @GSK under #WarpSpeed to develop & produce an investigational adjuvanted #COVID19 vaccine, including a demo of large-scale vaccine manufacturing w/ an adjuvant to enhance vaccine effectiveness. https://t.co/xsDa5LTSJJ pic.twitter.com/Ag0WmMPeIz
— BARDA (@BARDA) July 31, 2020
Some great news for patients living with #eosinophilic diseases from @ApFEd and @EosinophilSoc as new ICD-10-CM codes are available. 👏👏 Click below to learn more.👇 https://t.co/iynAKeULoD
— GSK US (@GSKUS) September 10, 2020
We’re proud of Gertrude Elion and our legacy of #innovation. Thanks for sharing @NatGeo! https://t.co/tSg23SAcI7
— GSK US (@GSKUS) September 10, 2020
We’re partnering with @23andMe to focus on genetics to better understand the root cause of disease. Treatments validated by #genetics are at least 2x as likely to succeed. #STATHealthTech #Technology #Innovation Watch this to learn more 👇 pic.twitter.com/kSDopfAci3
— GSK US (@GSKUS) September 9, 2020
We’re excited to be joining the #STATHealthTech Summit next week to talk about our collaboration with @23andMe. https://t.co/ex114mMi7w
— GSK US (@GSKUS) September 4, 2020
Thanks to our #ScientistHeroes like David, we’re using our scientific expertise to fight #COVID19. He’s worked on infectious diseases his entire career & now leads a team to identify medicines in our portfolio that may have application against the virus. https://t.co/yE1gQRlGXb pic.twitter.com/iLFIKgr1bV
— GSK US (@GSKUS) September 2, 2020
We proudly support the efforts of @WomenInGovt, for talking to their constituents about #vaccines & following @CDCgov guidance on recommended immunizations.
Listen here 🔊 https://t.co/vVGhoHqr6n #ivax2protect— GSK US (@GSKUS) August 29, 2020
In addition to our agreement with the US Government, through our participation in the Access to #COVID19 Tools Accelerator, we continue our commitment to making our adjuvant available using mechanisms that offer fair access for people across the world. https://t.co/77uS2xQTVH pic.twitter.com/w14YhaqvKp
— GSK US (@GSKUS) July 31, 2020
#DYK: Scientists, like Amanda, are learning how our immune systems respond to #COVID19 by studying the antibodies of survivors. This work could help us find new medicines to fight the virus. #ScientistHeroes pic.twitter.com/Dy8cMaSHMh
— GSK US (@GSKUS) August 11, 2020
#News for #media: When it comes to #inequity, we believe we have a role to play. Today, we’re proud to announce a 10M commitment over the next 10 yrs. to help increase the number of Black, Latin-X and female students in #Philly who become #STEM professionals.
— GSK US (@GSKUS) August 12, 2020